文献速递食管胃疾病与幽门螺杆菌

美国幽门螺杆菌感染一线治疗中伏诺拉生方案与利福布汀方案及其他方案的成本效果分析

Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States.
PubMed 文献 · Am J Gastroenterol · 2022-12-14

该研究从美国医疗支付方视角,采用状态转换马尔可夫模型,比较克拉霉素三联、铋剂四联、伏诺拉生双联、伏诺拉生三联和利福布汀三联方案一线根除幽门螺杆菌的成本效果,周期2个月,时限20年,贴现率3%。结果显示利福布汀三联方案成本更低且效果优于克拉霉素三联、铋剂四联和伏诺拉生双联方案;伏诺拉生三联方案较利福布汀三联方案成本更高但QALY略高,增量成本效果比为22,573美元/QALY,在支付意愿阈值50,000至150,000美元/QALY下净货币效益最高,最具成本效果。

要点

  • 利福布汀三联方案成本更低且效果优于克拉霉素三联、铋剂四联和伏诺拉生双联方案。
  • 伏诺拉生三联方案较利福布汀三联方案成本更高但QALY略高,增量成本效果比为22,573美元/QALY。
  • 在美国支付方视角下,伏诺拉生三联方案净货币效益最高,在支付意愿阈值50,000至150,000美元/QALY下最具成本效果。

核心结论

  • 从美国医疗支付方视角,伏诺拉生三联方案根除幽门螺杆菌可提供最大的净健康和货币效益。

研究设计与样本

  • 研究采用状态转换马尔可夫模型进行成本效果分析,比较克拉霉素三联、铋剂四联、伏诺拉生双联、伏诺拉生三联和利福布汀三联方案一线根除幽门螺杆菌的效果。
  • 模型周期长度为2个月,时限20年,成本以2022年美元表示,并应用3%贴现率计算未来成本和QALY的现值。

主要发现

  • 利福布汀三联方案较克拉霉素三联、铋剂四联和伏诺拉生双联方案成本更低且更有效,因而占据优势。
  • 伏诺拉生三联方案较利福布汀三联方案成本更高(1,172美元 vs 1,048美元)且QALY更高(14.262 vs 14.256),增量成本效果比为22,573美元/QALY。
  • 伏诺拉生三联方案在支付意愿阈值50,000至150,000美元/QALY下净货币效益最高,最具成本效果,其次为利福布汀三联方案。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The economic and clinical implications of eradicating Helicobacter pylori ( H. pylori ) with vonoprazan-based and rifabutin-based regimens vs other existing prepackaged first-line treatment options in the United States are unknown. Therefore, we evaluated the cost-effectiveness of vonoprazan-based and rifabutin-based and other prepackaged regimens for the first-line treatment of H. pylori from the perspective of US healthcare payers. METHODS: We used the state-transition Markov model to conduct a cost-effectiveness analysis of H. pylori eradication with clarithromycin triple, bismuth quadruple, vonoprazan dual, vonoprazan triple, and rifabutin triple regimens. In a cycle length of 2 months, the model estimated the expected costs (expressed in 2022 US$), expected quality-adjusted life-years (QALY), incremental cost-effectiveness ratios, and expected net monetary benefit over 20 years. In addition, we accounted for the present value of future costs and QALY by applying a 3% discounting rate. RESULTS: In this study, rifabutin triple therapy had a lower expected cost but was more effective than clarithromycin triple, bismuth quadruple, and vonoprazan dual regimens; hence, it dominated them. Vonoprazan triple therapy had a higher expected cost (US$ 1,172 vs US$ 1,048) and expected QALY (14.262 vs 14.256) than rifabutin triple therapy, yielding an estimated incremental cost-effectiveness ratio of US$ 22,573/QALY. The study suggested that vonoprazan triple treatment had the highest expected net monetary benefit and was the most cost-effective at willingness-to-pay thresholds between US$50,000 and US$150,000 per QALY, followed by rifabutin triple therapy. DISCUSSION: H. pylori infection eradication with vonoprazan triple therapy would provide the greatest net health and monetary benefit from the perspective of US healthcare payers.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Yunusa I, Love BL. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States. Am J Gastroenterol. 2022. PMID: 36693030. doi:10.14309/ajg.0000000000002146

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。